Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
5.42 USD | +2.85% | -3.04% | +15.32% |
May. 14 | Aprea Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
May. 02 | Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza as Chief Medical Officer | CI |
Financials (USD)
Sales 2024 * | 267K | Sales 2025 * | 267K | Capitalization | 28.62M |
---|---|---|---|---|---|
Net income 2024 * | -17M | Net income 2025 * | -22M | EV / Sales 2024 * | 107 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 107 x |
P/E ratio 2024 * |
-1.99
x | P/E ratio 2025 * |
-3.43
x | Employees | 7 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 81.81% |
Latest transcript on Aprea Therapeutics, Inc.
1 day | +2.85% | ||
1 week | -3.04% | ||
Current month | +6.27% | ||
1 month | +5.86% | ||
3 months | -13.69% | ||
6 months | +44.67% | ||
Current year | +15.32% |
Managers | Title | Age | Since |
---|---|---|---|
Oren Gilad
CEO | Chief Executive Officer | 56 | 22-04-30 |
John Hamill
DFI | Director of Finance/CFO | 60 | 23-01-29 |
Zeev Weiss
PRN | Corporate Officer/Principal | 62 | 22-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bernd Seizinger
BRD | Director/Board Member | 67 | 14-12-31 |
John Henneman
BRD | Director/Board Member | 62 | 19-07-31 |
Rifat Pamukcu
BRD | Director/Board Member | 66 | 22-04-30 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-20 | 5.42 | +2.85% | 355 |
24-05-17 | 5.27 | -5.72% | 8,153 |
24-05-16 | 5.59 | -3.62% | 14,751 |
24-05-15 | 5.8 | -1.53% | 11,445 |
24-05-14 | 5.89 | +5.37% | 8,820 |
Delayed Quote Nasdaq, May 20, 2024 at 09:53 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+15.32% | 28.62M | |
+38.44% | 50.93B | |
-0.34% | 42.12B | |
+49.62% | 42.05B | |
-7.20% | 29.18B | |
+12.83% | 26.02B | |
-22.48% | 18.9B | |
+8.42% | 13.21B | |
+24.84% | 12.17B | |
+30.09% | 12.16B |
- Stock Market
- Equities
- APRE Stock